A Phase 1, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects.

Trial Profile

A Phase 1, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Tivantinib (Primary) ; Caffeine; Digoxin; Midazolam; Omeprazole; Vitamin K; Warfarin
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 23 Oct 2013 Results presented at the 25th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
    • 01 Sep 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Jun 2012 Additional lead trial investigator (Puzanov I) identified as reported by Vanderbilt-Ingram Cancer Center record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top